App-Quantinova.ai

Risk factors for febrile neutropenia in cancer patients treated with chemotherapy.

Leila Family - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Filgrastim

Hospital volume and post-discharge mortality in Medicare beneficiaries aged 65 and older with acute leukemia.

Michael P Thompson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Non-adherence and health outcomes in women treated with oral endocrine therapy for breast cancer.

Daniel M. Geynisman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Predicting real-world effectiveness using overall survival and progression-free survival-based clinical trial efficacy measures.

Jason Shafrin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Implementing the patient reported outcomes measurement information system (PROMIS) global health scale in the adolescent and young adult (AYA) oncology population.

Joseph R. Henderson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Burden of febrile neutropenia hospitalizations (FNH) in U.S. clinical practice, by use and patterns of colony-stimulating factor prophylaxis (CP).

Derek Weycker - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Depression in patients with a metastatic cancer: Analysis of 796,072 cases.

Eric Adjei Boakye - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

30 day readmissions in cancer patients in United States.

Kathan Mehta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A multicenter study of patients decisional control preferences in patients with advanced cancer.

Sriram Yennu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes.

Vikram Kurra - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Medical Scribes in a Community Oncology Clinic.

Rachel E. Lerner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Older adults perspectives on incorporating life expectancy in cancer screening.

Kimberley Lee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Lean thinking: Exploring the volume of overhead and supplementary tasks (OST) in cancer care (CC) in the oncology outpatient encounter (OOE) in two tertiary centres.

Geoffrey David Peters - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Doing better with less: Can a quality improvement intervention to increase adherence to evidence-based cancer screening guidelines reduce health care costs?

Vineeth Sukrithan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Impact of industry funding and collaboration in oncology RCTs.

Anne Linker - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Frequency and risk factors for tyrosine kinase inhibitorassociated cardiotoxicity.

Peter J. Hurley - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

Predicting venous thromboembolism in hospitalized cancer patients: a risk assessment tool.

Rushad Patell - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Bone density screening in postmenopausal women with early-stage breast cancer on aromatase inhibitors.

Jamie Stratton - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of hospital volume on mortality rates amongst neutropenic cancer patients within the United States.

Yaacov Richard Lawrence - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A patient safety approach to assessing adverse events in oncology: Results from CHARM (Cancer Harm) study.

Allison Nicole Lipitz Snyderman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts